The relationship between Mycobacterium avium complex (MAC) infection of blood and bone marrow was studied in human immunodeficiency virus-infected patients before and during treatment. Quantitative cultures were obtained at baseline from 17 persons with newly detected MAC bacteremia. Serial blood cultures were obtained, and a second bone marrow sample was obtained at 4 or 8 weeks. At baseline, the median MAC load in bone marrow core samples was 3 log 10 higher than in blood. Bone marrow MAC loads ranged widely (866-847,315 cfu/g), and no significant correlation was found between MAC load in blood and that in bone marrow core samples. MAC loads in bilateral bone marrow biopsy samples from 7 subjects were highly correlated. MAC loads declined in blood and bone marrow at similar rates during therapy, but blood was sterilized before bone marrow. Length of survival was inversely associated with initial bone marrow core MAC load but not with blood MAC load. Initiation of treatment when tissue MAC load is low may increase the likelihood of favorable clinical outcome.
trials that included macrolides [12] [13] [14] [15] showed that MAC treatment effectively reduces the number of organisms in the blood and improves MAC-related symptoms. More recently, macrolide-based combinations have improved survival compared with older regimens [16] . However, the long-term outcomes remained poor, and relapse still was common [17] [18] [19] [20] . MAC infection remaining in tissue after the sterilization of blood is the probable source of relapses and may adversely influence longterm clinical responses. Blood culture results have not been clinically correlated with MAC loads in tissues before or during treatment, although an autopsy study suggested good correlation between levels of bacteremia and tissue infection after several months of therapy [21] .
The purpose of this study was to determine the relationship between the organism loads of MAC in blood and bone marrow at the time bacteremia is detected and during therapy. In addition, a substudy evaluated the uniformity of infection in bone marrow by comparison of quantitative culture results from samples obtained at 2 biopsy sites. Bone marrow biopsy was utilized in this study because it provides a relatively safe method to obtain a tissue sample with a high concentration of reticuloendothelial cells for quantitative culture.
Patients and Methods
Patient population. Eligible subjects were HIV-infected adults (у18 years old) in whom MAC bacteremia was first identified from samples obtained within 12 weeks before study entry. The following parameters were required within 7 days before study entry: serum creatinine !3.0 mg/dL, bilirubin !2.0 mg/dL, aspartate aminotransferase (AST)/alanine aminotransferase !5 times the upper limit of normal, absolute neutrophil count 1750 cells/mm 3 , platelet count 150,000 cells/mm 3 , and hemoglobin 17.0 g/dL. Patients could not have received any drug with activity against MAC for 110 days during the 8 weeks before study entry or any treatment or prophylaxis for MAC between the collection of the first MAC-positive blood sample and study entry. Persons who had received immunomodulators or cytotoxic chemotherapy within 8 weeks of study entry were excluded. Acute therapy for AIDS-related opportunistic infections or any other acute medical illnesses must have been completed 4 weeks before enrollment. Women were excluded if they were pregnant or breast-feeding.
Study methods. At baseline, 2 bone marrow core samples, 3-5 mL of bone marrow aspirate (from the same entry site), and 2 blood cultures were obtained from each patient. Patients were randomly assigned to undergo a second bone marrow biopsy after 4 or 8 weeks of treatment. At day 1 and weeks 1, 2, 4, 6, 8, 12, and 24, quantitative blood cultures and susceptibility testing were repeated, and plasma was obtained and stored at Ϫ70ЊC. At these visits and at weeks 36 and 48, patients completed a history and had a physical examination with routine hematology and chemistry tests. Patients kept a daily diary to record evening temperature, presence of night sweats, and antipyretic use. They were also asked to participate in a substudy to assess variation in quantitative MAC culture results between bone marrow biopsy samples obtained from the left and right iliac crests at baseline. HIV-1 load was determined from frozen plasma samples after the study ended.
Study therapy. After the baseline procedures, subjects received 500 mg of clarithromycin twice daily (provided by Abbott Laboratories, Abbott Park, IL) and 15 mg/kg of ethambutol daily, to a maximum of 1200 mg/day (provided by Lederle Laboratories, Pearl River, NY), for 48 weeks. At the discretion of the treating physician, rifabutin (300 mg/day) could be added to the treatment regimens of patients whose baseline MAC-associated signs and symptoms did not improve in the first 8 weeks.
Medication compliance. Compliance was assessed by counting medications returned at each study visit and was confirmed by medical event monitoring system electronic medication compliance container caps. For the purposes of analysis, patients were considered compliant if they received 160% of each study drug.
Cultures. All specimens for culture were shipped overnight to a central reference laboratory. Ten milliliters of blood was collected for culture in a sodium polyanethol sulfonate tube. Three to 5 mL of blood was inoculated into a blood culture vial (Bactec 13A; Becton Dickinson, Sparks, MD). The remaining blood was treated with sodium deoxycholate to lyse blood cells. The lysate was centrifuged at 3500 g and resuspended in Middlebrook 7H9 broth (Difco, Detroit) with serum albumin. Serial dilutions were made in 7H9 broth, and aliquots were inoculated in duplicate onto Middlebrook 7H11 agar supplemented with oleic acid-albumin-dextrose and catalase (Difco). The colonies on the plate were counted, and viable bacteria per milliliter of the original blood sample were calculated as colony-forming units per milliliter. The Bactec 13A media were incubated at 35ЊC and monitored for growth for 6 weeks with a Bactec 460 instrument (Becton Dickinson). Cultures were positive when the Bactec growth index was 30 and a smear of the growth medium was positive for acid-fast bacilli (AFB). A subculture was made onto 7H11 agar for species identification and susceptibility testing and was incubated at 35ЊC in 5% CO 2 for 8 weeks.
A portion of the bone marrow aspirate (3-5 mL) was placed in a 1.5-mL pediatric isolator tube (Wampole, Cranbury, NJ) for quantitative culture, and the rest was placed in 2 mL of 10% buffered formalin for histology. One bone marrow core sample was weighed and placed in nonbacteriostatic saline, and the second core was placed in 2 mL of fresh 10% buffered formalin. The core sample in saline was macerated, diluted in 7H9 broth, and inoculated in duplicate onto 7H11 agar. In addition, 0.1 mL of the suspension was inoculated into Bactec 12B media. The bone marrow cultures were incubated and examined as previously described [22] . Mycobacteria were identified with DNA probes (GenProbe, San Diego) or by conventional methods [23] .
Susceptibility testing. MAC isolates were tested against clarithromycin (2-32 mg/mL) and ethambutol (1-16 mg/mL) by use of a broth radiometric (Bactec) microdilution assay at pH 6.9 [24] . Each drug was tested at 5 concentrations, and the MIC was defined as the lowest concentration of drug that inhibited 99% of growth when a starting inoculum of ∼ cfu/mL was used; MAC 101 4 5 ϫ 10 type 1 was used for quality control. The breakpoint for clarithromycin resistance was defined as 32 mg/mL [24] .
MAC strain identification. Strains of MAC were identified by restriction fragment length polymorphism analysis and field inversion electrophoresis, by use of a procedure described by Arbeit et al. [25] and modified by Nash and Inderlied [26] .
Histopathology studies. Bone marrow core samples in formalin were decalcified with formic acid, paraffin-embedded, and processed. Sections (4 mm) were stained with Mayer's hematoxylin-eosin and Kinyoun AFB stains. In addition, an immunoperoxidase (IP) stain for mycobacteria with rabbit polyclonal antibodies to M. paratuberculosis (a subspecies of M. avium; Dako, Carpinteria, CA) was used by standardized technique [27] . All sections were examined by a hematopathologist to determine specimen quality, cell types, presence of granulomas, and any other abnormalities. The presence of AFB-or IP-staining material was graded 1ϩ to 4ϩ.
HIV load. Plasma HIV-1 RNA levels were measured in a central laboratory (Laboratory Corp. of America, Research Triangle Park, NC), by use of a reverse-transcriptase polymerase chain reaction kit (Amplicor, HIV-1 MONITOR assay; Roche Molecular Systems, Branchburg, NJ) with a lower limit of quantitation of 400 copies/mL.
Statistical methods. The associations between categorical variables and between continuous variables were assessed by use of Fisher's exact x 2 test and Spearman's correlation coefficient, respectively. The 7H11 plate cultures negative for MAC were scored as 0.1 cfu/mL if Bactec-positive and as 0.01 cfu/mL if Bactecnegative. Rates of decline were estimated from a repeated-measures model that included a random intercept effect for each subject [28] . Median time to events was estimated by the Kaplan-Meier method. The log rank test was used to assess potential covariates [29] . All computations were done by use of SAS software [30] .
Results

Baseline Results
Patient characteristics. Eighteen patients were enrolled between July 1993 and March 1995 at 4 participating centers. One person was excluded as ineligible because the baseline blood culture was negative. A summary of patient characteristics is shown in table 1. Eleven patients were enrolled on the basis of routine surveillance blood cultures, and, in general, symptoms of DMAC disease were mild or absent at baseline. Fever was the most common symptom reported, but only 4 of 17 subjects had a measured temperature у37.8ЊC (range, 37.8-38.7) at study entry. At baseline, the mean CD4 ϩ lymphocyte count was 15 cells/mm 3 , and the mean HIV-1 RNA concentration was 5.08 log 10 copies/mL. At study entry, 9 of 17 patients were receiving a single nucleoside reverse-transcriptase inhibitor; the remaining subjects were not receiving antiretroviral therapy.
Microbiology data. MAC was isolated from all baseline blood and bone marrow specimens obtained from the 17 eligible subjects. All isolates were M. avium except for the isolates from 1 patient. M. intracellulare was identified from this patient's samples, and M. avium was also isolated from the day 1 blood culture. The MAC load in 1 patient's baseline bone marrow core sample could not be calculated because of a weighing error that could not be corrected. This patient's bone marrow aspirate MAC load was the lowest of all baseline aspirate cultures. Table 2 shows each patient's quantitative MAC culture results at baseline and at weeks 4 and 8, HIV-1 results at baseline, and clinical status at the end of the study.
The median log 10 MAC loads (and ranges) at baseline were 1.57 (Ϫ1.00 to 3.14) cfu/mL for blood, 2.68 (0.90-4.20) cfu/mL for bone marrow aspirate, and 4.60 (2.94-5.93) cfu/g for bone marrow core specimens. The median difference between log 10 results for baseline bone marrow core and blood cultures was 2.70 (range, 1.46-4.91) cfu/mL or cfu/g. At baseline, the quantitative culture results for bone marrow core and blood samples were not significantly correlated (Spearman's correlation coefficient , ), but the bone marrow aspirate and r ϭ .19 P ϭ .48 blood culture results were significantly correlated ( , r ϭ .53 ; figure 1). A significant correlation was found between P ϭ .03 the bone marrow core and aspirate culture results ( , r ϭ 0.58 ). No statistically significant correlations were found P ϭ .02 between the core MAC load and biopsy specimen weight or any of the following baseline characteristics: presence of fever or fatigue, weight, Karnofsky score, AST, alkaline phosphatase, CD4 cell count, or HIV-1 RNA concentration. However, the detection of a weak correlation may have been limited because of the small sample sizes.
Bilateral bone marrow biopsies. MAC loads in core biopsy specimens and aspirates obtained at baseline from the right and left iliac crests of 7 patients were compared to determine the uniformity of MAC infection. The same-patient log 10 SDs for core and aspirate cultures were ϩ0.31 cfu/g and ϩ0.28 cfu/mL, respectively, corresponding to an approximately 4-fold variation between bilateral samples.
Bone marrow histology. At least 1 core specimen from each patient and 23 (96%) of the 24 total baseline core specimens contained bone marrow elements. No bone marrow elements were present in the baseline aspirates from 9 (53%) of 17 patients and in 13 (54%) of 24 aspirates. Mature, fully formed granulomas were observed in the bone marrow core samples from 2 (12%) of 17 patients. No differences in histopathology were observed between the left and right biopsy specimens. AFB-or IP-staining bacilli were observed in у1 sample from 9 (53%) of 17 patients and in 13 (54%) of the 24 baseline core biopsy specimens. No difference in sensitivity existed between the AFB and IP stains. Both were significantly more likely to be positive when the core MAC load was 115,000 cfu/g (8/10 patients) and negative when the core MAC load was !15,000 cfu/g (5/6 patients;
). P ϭ .035
Response to Treatment
Evaluable patients. Fourteen patients were compliant and 3 noncompliant with study therapy, according to study criteria (see Patients and Methods); noncompliant patients were excluded from all response-to-treatment analyses. Among the 14 compliant subjects, compliance was 62%-100% (median, 93%) for clarithromycin and 74%-100% (median, 100%) for ethambutol. Among the 3 noncompliant patients, compliance for clarithromycin ranged from 12% to 51%. Only 1 subject received a 3-drug regimen (rifabutin was started 4 months into MAC study treatment). Three compliant patients were excluded from the analysis of the rate of decline in MAC load for the following reasons: the MAC load in the baseline core sample of 1 patient could not be calculated because of a weighing error, 1 patient withdrew from the study before the second biopsy, and the MAC load in the second core sample from 1 patient could not be determined because of staphylococcal overgrowth. The baseline characteristics of the 6 excluded patients were not statis- Table 2 . Baseline and follow-up microbiologic and clinical data for individual patients. Correlation of Mycobacterium avium complex (MAC) load in blood with MAC load in bone marrow core and aspirate specimens at baseline. Quantitative culture results for blood and bone marrow aspirate were significantly correlated ( , ), but the r ϭ .53 P ϭ .03 results for blood and bone marrow core biopsy specimens were not ( , ). MAC loads were higher in both bone marrow core r ϭ .19 P ϭ .48 and aspirate specimens than in the corresponding blood specimen for all patients. tically different from those of the 11 patients included in the rate-of-decline analysis.
Rates of decline in MAC loads. Figure 2A -2C depicts the changes in MAC load for each type of specimen obtained from the 11 evaluable subjects. The baseline MAC loads for each type of sample were not significantly different between the randomization groups (table 3). The mean MAC load was greater in blood obtained from the week 4 patients (1.70 log cfu/mL) than in blood from the week 8 patients (0.93 log 10 cfu/mL), but this difference was not statistically significant ( ). The P ϭ .16 rates of decline in blood and bone marrow samples were not statistically different between the 2 groups, suggesting that the rates of decline during the first and second 4 weeks of treatment were similar. By use of repeated measures models, including all evaluable patients, the log 10 rate of decline and SE over 8 weeks was cfu/mL/week for blood, cfu/mL/ 0.36 ‫ע‬ 0.03 0.30 ‫ע‬ 0.07 week for bone marrow aspirate, and cfu/g/week for 0.29 ‫ע‬ 0.06 bone marrow core ( figure 2D ). The rates of decline for the 3 specimen types were not statistically different ( ) from a P ϭ .34 common rate of decline (log 10 0.34 cfu/g or mL/week) and were independent of the baseline MAC load.
Sterilization of blood and bone marrow. Among the 7 evaluable patients in the week 4 bone marrow biopsy group, 2 had sterile blood cultures at week 4, and 6 had sterile blood cultures at week 8, but all 7 remained bone marrow culture-positive at week 4. Although 2 patients in the week 8 biopsy group were not included in the rate-of-decline analysis because MAC load in a bone marrow core sample could not be calculated, these subjects were included in the assessment of sterilization. Among the 6 compliant patients in the week 8 biopsy group, all had sterile blood cultures, but only 2 had sterile bone marrow cultures at week 8. Among all compliant patients, the mean time to sterilization of blood was 7.0 ‫7.0ע(‬ SE) weeks.
Characteristics of MAC isolates. Selected blood and bone marrow isolates were obtained from all subjects at baseline and during therapy, and all isolates from the same person had identical macrorestriction patterns of genomic DNA. The MICs for clarithromycin and ethambutol were determined for 1150 isolates. No significant differences in MICs were found between blood and bone marrow isolates collected from the same person during the study. Resistance to clarithromycin ( mg/ MIC ϭ 32 mL) was not detected, except in a bone marrow isolate obtained from a patient who relapsed at week 40.
MAC loads and levels of HIV-1 RNA. The mean baseline HIV-1 RNA level was 5.08 log 10 copies/mL among the 11 persons in the MAC load rate-of-decline analysis. Seven of these subjects were receiving antiretroviral therapy with a single nucleoside reverse-transcriptase inhibitor before enrollment. Two additional patients began antiretroviral monotherapy after study entry, 1 at week 12 and 1 at week 36. The estimated mean log 10 rate of change in HIV-1 RNA levels by repeated-measures modeling was 0.01 ‫20.0ע(‬ SE; 95% confidence interval [CI], Ϫ0.03 to 0.05) log 10 copies/mL/week over the first 8 weeks. No statistically significant correlation was found between individual patient changes in HIV load and individual patient changes in MAC load of bone marrow core, bone marrow aspirate, or blood.
Patient survival. Among the 14 treatment-compliant patients, the mean survival time during the 48-week study period was 37. sociation with the baseline MAC load in bone marrow core ( ). None of the 7 persons with baseline core MAC loads P ϭ .02 !20,000 cfu/g (including the 1 patient whose baseline core MAC load was not quantitated but was presumed to be !20,000 cfu/ g based on the aspirate results) died during the 48-week study period, although 1 was lost to follow-up after week 38. One patient died 8 months after study completion of central nervous system lymphoma. No evidence of MAC infection was found on autopsy, which included extensive tissue examinations. Of the 7 subjects with baseline core MAC loads 120,000 cfu/g, only 1 was known to have survived beyond week 48. Four died before week 48. Two were lost to follow-up after 3 and 24 weeks, respectively, and both were in severely deteriorating health at their last study evaluation. No statistically significant associations were found between survival time and baseline aspirate or blood MAC loads or baseline HIV-1 RNA levels.
Discussion
This study was designed to clinically evaluate the course of DMAC disease before and during antimicrobial therapy by determination of the quantitative relationship between MAC loads in blood and tissue. All subjects had higher MAC loads in bone marrow than in blood, and the MAC load in bone marrow core samples was, on average, 1000-fold higher than that in blood. The presence of higher MAC loads in bone marrow is not surprising, because bone marrow is expected to have a higher concentration of infectable cells. More notably, the study patients had a wide range of bone marrow core MAC loads (866-847,315 cfu/g) at the time of detectable bacteremia. Although some subjects had high MAC loads in bone marrow at the time low-grade bacteremia was detected, several others had relatively low bone marrow loads at the time of sustained bacteremia. These results indicate that some persons do not have overwhelming levels of infection in at least one type of tissue after detection of sustained bacteremia. This finding is in contrast to conclusions based on autopsy studies performed in the 1980s and the associated "spillover theory."
Also notable is the lack of correlation between MAC loads in bone marrow core and blood samples at baseline. These results indicate that quantitative blood cultures cannot be used to distinguish between patients with high and low tissue MAC loads before treatment. MAC loads in the baseline bone marrow core and aspirate samples were significantly correlated; thus, aspirates could be used as a measure of tissue MAC load if core samples are not available. However, the median aspirate MAC load was 1200-fold lower than the core load, and aspirates are not as sensitive as core samples for the detection of very low MAC levels in bone marrow. The higher MAC loads in bone marrow core samples probably reflect a higher concentration of cells likely to be infected with MAC. Ninety-six percent of baseline core samples had identifiable marrow elements, compared with 54% of aspirate samples. Aspirate MAC loads also were significantly correlated with blood MAC loads, probably because aspirates contain a mixture of bone marrow elements and peripheral blood (which was apparent on visual and histologic examination). In contrast, microscopic examination of bone marrow core samples rarely revealed contamination with peripheral blood cells.
Bilateral biopsies were performed at baseline to assess the uniformity of MAC infection in bone marrow. If MAC infection is not uniform, sampling differences could lead to false conclusions concerning the intensity of bone marrow infection and the quantitative relationship between blood and bone marrow MAC loads. Bilateral biopsy specimens were obtained from 7 patients, and the same-patient variation between right and left samples averaged 0.3 log 10 cfu/g (∼4-fold). Havlir et al. [31] showed that the results of paired quantitative MAC blood cultures done within a single laboratory were highly reproducible, with an average within-patient variation of ∼1.8-fold. Although the 0.3 log 10 cfu/g variation between bilateral core MAC loads is somewhat greater than the expected experimental error, variation of this magnitude should allow clinically relevant use of a single biopsy to assess the intensity of MAC load in bone marrow. However, MAC load in bone marrow may not reflect the intensity of infection in other tissues.
The average rates of decline in MAC load during the first 8 weeks of treatment appear to be similar for bone marrow core and blood cultures (0.29 and 0.36 log 10 cfu/g or cfu/mL per week, respectively). The rates of decline in bone marrow and blood were independent of baseline MAC loads, indicating that the population density of bacilli in tissue is not likely to have a large influence on the effectiveness of MAC chemotherapy. The time to sterilization of bone marrow by chemotherapy appears to correlate with the baseline bone marrow MAC load but could not be predicted on the basis of blood culture response. At week 8, only 2/6 patients (both with very low bone marrow core MAC loads) had sterile bone marrow cultures, but all 6 evaluable patients had sterile blood cultures. Although the sterilization of blood occurred relatively rapidly (median, 7 weeks), the sterilization of bone marrow usually occurs considerably later, particularly in persons with higher MAC loads in bone marrow. Patients who have poor or intermittent compliance with therapy before sterilization of tissues are at high risk for relapse and are likely to relapse with a macrolide-resistant MAC isolate. Histopathologic findings were rare, and well-formed granulomas were uncommon in bone marrow core specimens, regardless of the level of MAC infection. These results are consistent with earlier studies of MAC-infected tissues from HIV-seropositive subjects [32, 33] . In a recent study of 82 bone marrow biopsy specimens from 76 persons, Kilby et al. [34] observed granulomas in only 27% of the culture-positive specimens. In the present study, AFB and IP staining had similar sensitivity for the detection of bacilli in bone marrow core samples. Relatively low levels of marrow infection (!15,000 cfu/g) were not reliably detected by either technique. This finding is consistent with the results of Kilby et al. [34] , who found that only 29% of mycobacterial culture-positive bone marrow samples were AFB-positive.
Torriani et al. [8] examined the relationship between blood and tissue MAC infection in an autopsy study of 44 subjects with MAC bacteremia. No evidence of MAC infection was detected by histologic examination of any tissues obtained from 30% of the subjects, and the risk of detectable histologic involvement was related to the duration of bacteremia. The investigators concluded that tissue burden at the time of initial bacteremia may be limited in many persons and that detectable MAC bacteremia may precede widespread tissue disease. Although this autopsy study assessed persons at a much later phase of MAC disease, the results of the present study are in agreement with the first of these conclusions. The two studies reach different conclusions concerning the frequency of MAC infection in tissues at the time of detectable bacteremia. In the present study, MAC was isolated from the bone marrow of all subjects at the time bacteremia was detected. This difference may be explained by the fact that Torriani et al. [8] used only histologic examination to detect MAC. On the basis of the results reported here, AFB staining is an insensitive method for the detection of low levels of tissue infection (!15,000 cfu/g). In a subsequent autopsy study, Torriani et al. [21] reported a sensitivity of 70% for the detection of AFB by stain, which Downloaded from https://academic.oup.com/jid/article-abstract/180/2/438/877672 by guest on 21 November 2018 could account for the 30% of tissues in which AFB was not detected.
In the second autopsy study by Torriani et al. [21] , blood and several tissues from 10 MAC-infected subjects who had received macrolide-based combination therapy were quantitatively cultured for MAC. MAC was isolated from the blood and tissues of 7, of whom 6 had had an episode of unresolved or recurrent bacteremia within 3 months of death. Four subjects had discontinued treatment before death (range, 0.7-6.8 months). The correlation between MAC load in blood and tissues was significant ( , ). The authors conr ϭ .88 P ϭ .002 cluded that blood culture is useful as a practical measure of the impact of chronic therapy on infected tissues. The present study evaluated the initial treatment of MAC and did not find such a correlation. As Torriani et al. [21] noted, their findings cannot be applied to the early phase of MAC treatment but only to chronic therapy.
Survival time was significantly associated with baseline bone marrow core MAC load ( ). Six of 7 persons with rel-P ϭ .02 atively low baseline MAC loads (!20,000 cfu/g) in bone marrow core samples survived у48 weeks after study entry. In contrast, 8 of 9 patients with higher core MAC loads (139,000 cfu/g) died or withdrew from the study in very poor health within 48 weeks, and most died within 6 months. Untreated MAC infection has been associated with decreased survival in HIVinfected persons [35, 36] , and patients receiving MAC prophylaxis have improved survival rates [37, 38] . High MAC load in tissues may be a cause of increased mortality or a noncausally associated factor. High MAC loads may contribute to mortality by enhancing immunodeficiency-related mechanisms that are not reversed by effective MAC treatment. Alternatively, persons with the highest tissue MAC loads may be more immunocompromised independently of MAC infection, and mortality may remain high despite effective MAC therapy. However, effective treatment of persons with comparatively low tissue MAC loads may interrupt the progression of mechanisms contributing to decreased survival. Improved methods for detection of early tissue infection could also improve therapeutic outcome. The survival analysis is limited by the small sample size and censoring of survival at 1 year. The baseline MAC load in blood did not correlate with survival, although a significant relationship has been reported [39] . It is likely that the relationship between blood MAC load and survival was not detected in the present study because of the small sample size. In contrast, a significant correlation between bone marrow core MAC load and survival was detected. This suggests that there may be a stronger relationship between bone marrow MAC load and survival than between blood MAC load and survival.
HIV-1 loads were high (mean, 5.08 log 10 copies/mL) at baseline among the study patients who received no antiretroviral therapy or nucleoside monotherapy. The 95% CI for the rate of change per week in mean log 10 HIV-1 RNA level during the first 8 weeks of MAC treatment (Ϫ0.03 to 0.05) indicates that the mean HIV load is unlikely to have decreased 10.24 logs or increased by 10.40 logs after 8 weeks, despite significant decreases in MAC loads. Also, the mean HIV load had not significantly decreased 24 weeks after study entry. Recent studies have indicated that mycobacterial infections increase HIV replication [40] [41] [42] . In a case-control study of nearly 200 HIVinfected subjects with or without MAC infection, Havlir et al. [43] showed that the onset of MAC bacteremia is associated with a small (0.4 log 10 copies/mL) but significant increase in HIV-1 RNA levels. Goletti et al. [44] showed that plasma HIV load increased 5-160-fold during the acute phase of M. tuberculosis disease in HIV-infected patients. Clinical studies also have suggested that effective antimycobacterial therapy may not decrease HIV replication. In studies of African patients with tuberculosis [45, 46] , HIV loads increased or did not change despite 6 months of effective tuberculosis treatment.
The incidence of MAC disease in HIV-infected persons has decreased dramatically since the introduction of potent antiretroviral therapy, which may result in restoration of protective immunity against MAC infection. An ongoing study (AIDS Clinical Trials Group Protocol 393) is evaluating the need for MAC maintenance therapy in persons who respond to potent anti-HIV therapy and in whom MAC is likely to have been eradicated from tissues after at least 12 months of macrolidebased treatment as assessed by bone marrow culture. Eradication of MAC from tissues may be possible with antimycobacterial chemotherapy, at least for patients with low initial MAC loads. For example, study patient 6 had no evidence of MAC in any tissues examined at autopsy after the study was completed. The results of this study also indicate that the likelihood and timing of tissue sterilization by MAC treatment cannot be determined from the blood culture response. On the basis of these findings, a bone marrow biopsy for MAC culture is advisable before MAC maintenance therapy is discontinued for persons who respond to potent antiretroviral treatment until more data are available. However, sterilization of bone marrow does not ensure that MAC has been eradicated from all tissues. Lymph nodes, liver, and spleen were found to be more heavily infected than bone marrow in autopsy studies [6, 21] .
A more complete understanding of the natural history and pathogenesis of this disease will require an improved knowledge of the specific host immune responses to MAC infection (particularly in tissues), predisposing immune defects, and organism virulence factors. In addition, the complex interplay among HIV infection, MAC disease, and host defenses must be better understood. Clinical trials are underway to further define the crucial immune mechanisms and to determine whether potent antiretroviral therapy restores MAC-specific protective immunity.
